Signatera™
Transforming the management of cancer with personalized testing
Signatera is a personalized, tumor-informed assay optimized to detect circulating tumor DNA (ctDNA) for molecular residual disease (MRD) assessment and recurrence monitoring for patients previously diagnosed with cancer, with broad utility for cancer management. This MRD assay is highly sensitive and personalized for each patient, to help inform important treatment decisions.
Knowing earlier matters
Each person’s cancer is as unique as their fingerprint. Signatera is a MRD blood test that is personalized to each patient’s set of tumor mutations and can identify earlier than traditional tools if cancer is still present. Knowing this information can help you have a more informed discussion with your doctor regarding your treatment journey.
How Signatera helps patients through their treatment
Scanxiety is very real for many patients previously diagnosed with cancer. Living scan to scan creates anxiety and fearful thoughts: is the cancer coming back? Through shared decision making, many patients are working closely with their doctors to incorporate Signatera into their treatment plan to provide additional information needed for confident decision making and to provide patients peace of mind between scans. Patient anxiety may be alleviated by gaining a greater understanding of their progress and feel more informed on how they apporach their treatment options.
Listen to Brook Bell’s story, a young CRC patient, discuss her experience using Signatera
Signatera is validated in multiple cancer types
I have colorectal cancer
If you have been diagnosed with colorectal cancer, learn more how to identify residual disease and detect relapse sooner with Signatera MRD testing
I am on immunotherapy
If you are undergoing immunotherapy and want to know how the Signatera MRD test can help monitor the effectiveness of your treatment
Is Signatera right for me?
If you have been diagnosed with cancer such as breast, ovarian, lung or melanoma and want to learn more how to identify residual disease and detect relapse sooner
Why Signatera?
Signatera is a blood MRD test used for cancer detection and surveillance. It is personalized for each patient. It is used for molecular residual disease assessment and for treatment response monitoring.
A doctor may order Signatera along with routine follow-up exams to determine whether:
- There are signs of cancer remaining in the body
- Treatment (e.g., chemotherapy, radiation) is working
- The cancer is recurring
How Signatera Works: a personalized and tumor informed approach to MRD surveillance
A one-time analysis of both blood and tissue determines your unique set of tumor mutations.
The MRD test is custom-built and personalized just for you, using your own tumor tissue.
Signatera MRD test detects small fragments of ctDNA each time it is ordered as part of your routine follow-up blood tests. Patients who are ctDNA positive by Signatera are more likely to relapse.
Understanding your Signatera test results
If you have metastatic cancer, a negative result may mean that your treatment was able to decrease the amount of cancer cells to undetectable levels, meaning the treatment has been effective.